313 related articles for article (PubMed ID: 7685416)
41. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
42. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin.
Leinonen J; Lövgren T; Vornanen T; Stenman UH
Clin Chem; 1993 Oct; 39(10):2098-103. PubMed ID: 7691441
[TBL] [Abstract][Full Text] [Related]
43. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
[TBL] [Abstract][Full Text] [Related]
44. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical finding of alpha-1-antichymotrypsin in tissues of benign prostatic hyperplasia and prostate cancer.
Tanaka M; Suzuki Y; Takaoka K; Murakami S; Suzuki N; Shimazaki J
Int J Urol; 1999 Dec; 6(12):600-6. PubMed ID: 10609542
[TBL] [Abstract][Full Text] [Related]
46. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
[TBL] [Abstract][Full Text] [Related]
47. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
Wolff JM; Scholz A; Boeckmann W; Jakse G
Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal evaluation of the complexed-to-total prostate specific antigen ratio in men with prostate disease. Effect of treatment.
España F; Martínez M; Royo M; Vera CD; Estellés A; Aznar J; Jiménez-Cruz JF
Eur J Cancer; 1998 Aug; 34(9):1375-80. PubMed ID: 9849420
[TBL] [Abstract][Full Text] [Related]
49. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex.
Wan XS; Xu YA; Ware JH; Kennedy AR
Prostate; 2003 Jul; 56(2):131-41. PubMed ID: 12746838
[TBL] [Abstract][Full Text] [Related]
50. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Onur R; Ilhan N; Orhan I; Ilhan N
World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
[TBL] [Abstract][Full Text] [Related]
51. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
[TBL] [Abstract][Full Text] [Related]
52. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.
Mitrunen K; Pettersson K; Piironen T; Björk T; Lilja H; Lövgren T
Clin Chem; 1995 Aug; 41(8 Pt 1):1115-20. PubMed ID: 7543033
[TBL] [Abstract][Full Text] [Related]
53. [Concentrations of free form and complex form of prostate-specific antigen in serum of alpha 2 macroglobulin deficient patients with prostatic carcinoma].
Kanoh Y; Jimbo S; Shibuya M; Matsuyama N; Mashiko T; Tanaka T; Egawa S; Ohtani H
Rinsho Byori; 1998 Sep; 46(9):923-9. PubMed ID: 9800478
[TBL] [Abstract][Full Text] [Related]
54. Value of prostate specific antigen alpha1-antichymotrypsin complex for the detection of prostate cancer in patients with a PSA level of 4.1-10.0 ng/mL: comparison with PSA-related parameters.
Miyake H; Hara S; Nomi M; Arakawa S; Kamidono S; Hara I
Int J Urol; 2001 Nov; 8(11):589-93. PubMed ID: 11903683
[TBL] [Abstract][Full Text] [Related]
55. The establishment and evaluation of luminescent-labelled immunometric assays for prostate-specific antigen-alpha 1-antichymotrypsin complexes in serum.
Wood WG; van der Sloot E; Böhle A
Eur J Clin Chem Clin Biochem; 1991 Dec; 29(12):787-94. PubMed ID: 1724606
[TBL] [Abstract][Full Text] [Related]
56. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
[TBL] [Abstract][Full Text] [Related]
57. Is free prostate-specific antigen helpful in the differential diagnosis of benign hyperplasia and cancer of the prostate?
Reiter W; Stieber P; Schmeller N; Nagel D; Schambeck C; Fateh-Moghadam A
Tumour Biol; 1997; 18(2):80-7. PubMed ID: 9222305
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma.
Froschermaier SE; Pilarsky CP; Wirth MP
Urology; 1996 Apr; 47(4):525-8. PubMed ID: 8638361
[TBL] [Abstract][Full Text] [Related]
59. [PSA:alpha 1-antichymotrypsin ratio/total PSA in the diagnosis of prostatic cancer in the range of total PSA from 4 to 10 ng/ml].
Martínez Sarmiento M; España F; Royo M; Estellés A; Aznar J; Vera Donoso CD; Medina P; Jiménez Cruz JF
Actas Urol Esp; 2001 Apr; 25(4):269-77. PubMed ID: 11455828
[TBL] [Abstract][Full Text] [Related]
60. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.
Björk T; Bjartell A; Abrahamsson PA; Hulkko S; di Sant'Agnese A; Lilja H
Urology; 1994 Apr; 43(4):427-34. PubMed ID: 7512295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
